Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02997202
Title A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS

Additional content available in CKB BOOST